2025 Q4 -tulosraportti
Vain PDF
5 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 612 | - | - | ||
| 724 | - | - | ||
| 333 | - | - | ||
| 10 | - | - | ||
| 6 | - | - |
Ylin
6,04VWAP
Alin
5,6VaihtoMäärä
5,8 1 002 055
VWAP
Ylin
6,04Alin
5,6VaihtoMäärä
5,8 1 002 055
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 002 055 | 1 002 055 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 002 055 | 1 002 055 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenThere is a nervousness in the market that is pulling down the stock. I am holding long-term in an exciting stock that has untold possibilities to go very high. I'll be on board when the train leaves. I won't be left behind on the platform like many will be when they are selling out now.
·9 t sittenTechnical analysis says the floor is now 4.90kr. Sounds low but BV is still far over a billion. Is it worth a billion at present is the big question?
·1 päivä sittenNo one can say I wasn't right...And guess what ?? Further down we shall so you know...
·23.2.What do you primarily want to see in the report?
·27.2.Didn't sell just recently, earlier. Maybe I'll take the profit and put it back into the company again when they come under 5.
·20.2.Take the opportunity to invest more now before the report
·20.2.Super positive on Cereno, but don't think the report will make any big difference. Have more faith in EAP/CU data towards the end of the quarter.·3 päivää sitten · MuokattuI have sold off myself.(not all) Hard to see that CU would be able to reverse the share price trend. Few patients. We can expect a continuation of the same results we have already received. The market did not like that result. One can also ask why only half of the patients continued with the preparation if it is so good?
16.2.16.2.Just a sad look for Cereno right now. The people spouting utter nonsense about the 10SEK valuation being justified and holding should be ashamed. It was always going to happen - small cap biotech just happens to live off of hype and news. When there is none and progress is slow, volume dies down and so does appreciation. Insert a couple of big players with exercisable warrants at cheaper than valuation cost and some others who are selling out of impatience or wanting to realize their gains and you have what we see here - a 30% valuation drop that won‘t be recovered for a while most likely. The future isn‘t all bleak. Of course not. The product has potential and new topline results etc. (if positive) will send this flying back up. Until then, we just have to hold on for the ride. There‘s no regulatory or financial reason for this to go „tits up“ right now, so no reason to panic. Where the evaluation ends up is purely speculative however.·20.2.Here was someone who doesn't think like me, so now I got curious! Let's eat the elephants one bite at a time. In my head, it won't be long until Cereno is a phase 2a company, with an approved study for phase 2b, CRO ready, money ready, I would say that only the planned start in q2 remains. What do you think might additionally remain before you would call them a phase 2b company? Where did you get the market value figure from? Who do you use for comparison? What factors do you base a 500mSEK valuation on? Let's take Edison's analysis as a starting point, which estimates that the company is currently worth 21kr. Now, I'm not saying I think this is correct, and I'm very interested in discussing this to understand better, but for the sake of hypothesis, let's say they have completely missed the mark on most points.(which I don't believe) Even if you remove 2/3 of their estimated value, we are still around the share price we see today. I can agree that there is a risk in the current financing, but everything I have seen from the management so far indicates that this is an extremely competent group who know what they are doing. With the lock up that has been done and the very creative financing, I assume they have some aces up their sleeve towards the summer. What do you think is the root of the financial situation? Also curious about the third elephant… but let's take that when we have gotten through these two. Anyway, cool that you come with other views, as long as we can have a good debate, the worst that can happen is that we learn something from each other.1 päivä sitten1 päivä sittenIm in a similar situation. An upside for Cerebo is that FDA has clarified that one ph3 trial may be enough in certain circumstances. That would obviously lower the cost to reg approval, but I sincerely hope they can offload their asset way ahead of that. Ideally last summer…
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
5 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenThere is a nervousness in the market that is pulling down the stock. I am holding long-term in an exciting stock that has untold possibilities to go very high. I'll be on board when the train leaves. I won't be left behind on the platform like many will be when they are selling out now.·9 t sittenTechnical analysis says the floor is now 4.90kr. Sounds low but BV is still far over a billion. Is it worth a billion at present is the big question?
- ·1 päivä sittenNo one can say I wasn't right...And guess what ?? Further down we shall so you know...
- ·23.2.What do you primarily want to see in the report?·27.2.Didn't sell just recently, earlier. Maybe I'll take the profit and put it back into the company again when they come under 5.
- ·20.2.Take the opportunity to invest more now before the report·20.2.Super positive on Cereno, but don't think the report will make any big difference. Have more faith in EAP/CU data towards the end of the quarter.·3 päivää sitten · MuokattuI have sold off myself.(not all) Hard to see that CU would be able to reverse the share price trend. Few patients. We can expect a continuation of the same results we have already received. The market did not like that result. One can also ask why only half of the patients continued with the preparation if it is so good?
- 16.2.16.2.Just a sad look for Cereno right now. The people spouting utter nonsense about the 10SEK valuation being justified and holding should be ashamed. It was always going to happen - small cap biotech just happens to live off of hype and news. When there is none and progress is slow, volume dies down and so does appreciation. Insert a couple of big players with exercisable warrants at cheaper than valuation cost and some others who are selling out of impatience or wanting to realize their gains and you have what we see here - a 30% valuation drop that won‘t be recovered for a while most likely. The future isn‘t all bleak. Of course not. The product has potential and new topline results etc. (if positive) will send this flying back up. Until then, we just have to hold on for the ride. There‘s no regulatory or financial reason for this to go „tits up“ right now, so no reason to panic. Where the evaluation ends up is purely speculative however.·20.2.Here was someone who doesn't think like me, so now I got curious! Let's eat the elephants one bite at a time. In my head, it won't be long until Cereno is a phase 2a company, with an approved study for phase 2b, CRO ready, money ready, I would say that only the planned start in q2 remains. What do you think might additionally remain before you would call them a phase 2b company? Where did you get the market value figure from? Who do you use for comparison? What factors do you base a 500mSEK valuation on? Let's take Edison's analysis as a starting point, which estimates that the company is currently worth 21kr. Now, I'm not saying I think this is correct, and I'm very interested in discussing this to understand better, but for the sake of hypothesis, let's say they have completely missed the mark on most points.(which I don't believe) Even if you remove 2/3 of their estimated value, we are still around the share price we see today. I can agree that there is a risk in the current financing, but everything I have seen from the management so far indicates that this is an extremely competent group who know what they are doing. With the lock up that has been done and the very creative financing, I assume they have some aces up their sleeve towards the summer. What do you think is the root of the financial situation? Also curious about the third elephant… but let's take that when we have gotten through these two. Anyway, cool that you come with other views, as long as we can have a good debate, the worst that can happen is that we learn something from each other.1 päivä sitten1 päivä sittenIm in a similar situation. An upside for Cerebo is that FDA has clarified that one ph3 trial may be enough in certain circumstances. That would obviously lower the cost to reg approval, but I sincerely hope they can offload their asset way ahead of that. Ideally last summer…
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 612 | - | - | ||
| 724 | - | - | ||
| 333 | - | - | ||
| 10 | - | - | ||
| 6 | - | - |
Ylin
6,04VWAP
Alin
5,6VaihtoMäärä
5,8 1 002 055
VWAP
Ylin
6,04Alin
5,6VaihtoMäärä
5,8 1 002 055
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 002 055 | 1 002 055 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 002 055 | 1 002 055 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
5 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenThere is a nervousness in the market that is pulling down the stock. I am holding long-term in an exciting stock that has untold possibilities to go very high. I'll be on board when the train leaves. I won't be left behind on the platform like many will be when they are selling out now.·9 t sittenTechnical analysis says the floor is now 4.90kr. Sounds low but BV is still far over a billion. Is it worth a billion at present is the big question?
- ·1 päivä sittenNo one can say I wasn't right...And guess what ?? Further down we shall so you know...
- ·23.2.What do you primarily want to see in the report?·27.2.Didn't sell just recently, earlier. Maybe I'll take the profit and put it back into the company again when they come under 5.
- ·20.2.Take the opportunity to invest more now before the report·20.2.Super positive on Cereno, but don't think the report will make any big difference. Have more faith in EAP/CU data towards the end of the quarter.·3 päivää sitten · MuokattuI have sold off myself.(not all) Hard to see that CU would be able to reverse the share price trend. Few patients. We can expect a continuation of the same results we have already received. The market did not like that result. One can also ask why only half of the patients continued with the preparation if it is so good?
- 16.2.16.2.Just a sad look for Cereno right now. The people spouting utter nonsense about the 10SEK valuation being justified and holding should be ashamed. It was always going to happen - small cap biotech just happens to live off of hype and news. When there is none and progress is slow, volume dies down and so does appreciation. Insert a couple of big players with exercisable warrants at cheaper than valuation cost and some others who are selling out of impatience or wanting to realize their gains and you have what we see here - a 30% valuation drop that won‘t be recovered for a while most likely. The future isn‘t all bleak. Of course not. The product has potential and new topline results etc. (if positive) will send this flying back up. Until then, we just have to hold on for the ride. There‘s no regulatory or financial reason for this to go „tits up“ right now, so no reason to panic. Where the evaluation ends up is purely speculative however.·20.2.Here was someone who doesn't think like me, so now I got curious! Let's eat the elephants one bite at a time. In my head, it won't be long until Cereno is a phase 2a company, with an approved study for phase 2b, CRO ready, money ready, I would say that only the planned start in q2 remains. What do you think might additionally remain before you would call them a phase 2b company? Where did you get the market value figure from? Who do you use for comparison? What factors do you base a 500mSEK valuation on? Let's take Edison's analysis as a starting point, which estimates that the company is currently worth 21kr. Now, I'm not saying I think this is correct, and I'm very interested in discussing this to understand better, but for the sake of hypothesis, let's say they have completely missed the mark on most points.(which I don't believe) Even if you remove 2/3 of their estimated value, we are still around the share price we see today. I can agree that there is a risk in the current financing, but everything I have seen from the management so far indicates that this is an extremely competent group who know what they are doing. With the lock up that has been done and the very creative financing, I assume they have some aces up their sleeve towards the summer. What do you think is the root of the financial situation? Also curious about the third elephant… but let's take that when we have gotten through these two. Anyway, cool that you come with other views, as long as we can have a good debate, the worst that can happen is that we learn something from each other.1 päivä sitten1 päivä sittenIm in a similar situation. An upside for Cerebo is that FDA has clarified that one ph3 trial may be enough in certain circumstances. That would obviously lower the cost to reg approval, but I sincerely hope they can offload their asset way ahead of that. Ideally last summer…
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 612 | - | - | ||
| 724 | - | - | ||
| 333 | - | - | ||
| 10 | - | - | ||
| 6 | - | - |
Ylin
6,04VWAP
Alin
5,6VaihtoMäärä
5,8 1 002 055
VWAP
Ylin
6,04Alin
5,6VaihtoMäärä
5,8 1 002 055
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 002 055 | 1 002 055 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 002 055 | 1 002 055 | 0 | 0 |